A Post-Marketing Observational Study to Evaluate Safety and Effectiveness of Upadacitinib in Adolescent Patients Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Latest Information Update: 22 Jun 2024
At a glance
- Drugs Upadacitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors AbbVie
Most Recent Events
- 22 Dec 2021 Planned primary completion date changed from 28 Feb 2026 to 31 Mar 2026.
- 15 Nov 2021 Planned End Date changed from 28 Feb 2026 to 31 Mar 2026.
- 04 Oct 2021 Status changed from not yet recruiting to recruiting.